HAS Healthcare Advanced Synthesis SA (“HAS”), a leading international developer and producer of active pharmaceutical ingredients (APIs), high-potency APIs, and anticancer compounds acquired Cerbios-Pharma SA (“Cerbios”), a globally recognised manufacturer of chemical and biological APIs, including in the rapidly expanding area of antibody drug conjugates.
This strategic transaction marks a significant milestone for the two companies and sets the stage for the creation of a leading global solutions provider in the Contract Development and Manufacturing Organization industry.
Who we partnered with
HAS, owned by the Braglia family, acquired Cerbios which was itself owned by several families. 65 Equity Partners backed the merger, partnering with these family businesses and entrepreneurs in this acquisition.
What attracted us to the business
The alliance of the two Swiss-based companies, both with a global market presence, will drive innovation, accelerate extensive high-quality production capabilities, and deliver the cutting-edge chemical and biological expertise, technical excellence, and a wider range of services to address the dynamic needs of the global pharmaceutical industry.
Our value creation strategy
With the strategic backing of 65 Equity Partners to drive long-term company growth and innovation, the new group is uniquely positioned for growth in an industry underpinned by strong structural tailwinds.
Website: hashealthcare.com